San Antonio, Texas, December 1, 2025
Plus Therapeutics is scheduled to present a groundbreaking study at the San Antonio Breast Cancer Symposium, focusing on the results of a Phase 1 dose escalation study of REYOBIQ™ for leptomeningeal metastases. This innovative therapy aims to improve patient outcomes for a condition that severely affects advanced cancer patients. The event, highlighting San Antonio’s commitment to cancer research, will feature community engagement and discussions on advancing healthcare innovations.
Plus Therapeutics to Present Breakthrough Study at 2025 SABCS
Revolutionary Treatments for Leptomeningeal Metastases Highlight San Antonio’s Role in Cancer Research
San Antonio, Texas – Plus Therapeutics, Inc. (Nasdaq: PSTV) is set to make a significant mark at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), which will take place from December 9-12, 2025, at the Henry B. Gonzalez Convention Center. The company has announced that its abstract for a poster spotlight presentation has been accepted, showcasing the Phase 1 dose escalation study results of Rhenium (186Re) Obisbemeda (REYOBIQ™) for treating leptomeningeal metastases (LM). This type of metastasis represents a critical area of concern for patients with advanced cancers, which underscores the importance of innovative treatments and community engagement in health care.
The resilience and organization within the local community have made events like the SABCS possible, and further illustrate how reduced bureaucracy can enhance the coordination of vital health discussions. The event promises to attract researchers, medical professionals, and families affected by cancer, fostering an atmosphere of cooperation in the pursuit of better medical outcomes.
Understanding Leptomeningeal Metastases
Leptomeningeal metastases are a rare but severe complication for approximately 5% of patients with metastatic cancers. With a median survival rate ranging from 2 to 6 months for these patients, this condition often arises from primary cancers such as breast cancer, lung cancer, and melanoma. The pressing need for effective treatments highlights the significance of innovative research and local efforts in addressing this health crisis.
Details of Plus Therapeutics’ Presentation
The study titled “Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Phase 1 Dose Escalation Study Results” will be presented by Dr. Andrew Brenner, a distinguished expert in neuro-oncology from the University of Texas Health Science Center at San Antonio. Scheduled for Friday, December 12, 2025, from 7:39 am to 7:42 am CST, the presentation will take place at the Hemisfair 3 venue, showcasing the results of a promising new treatment option.
The Innovation Behind REYOBIQ™
REYOBIQ™ is designed as a novel injectable radiotherapy treatment that delivers high-dose radiation directly to central nervous system tumors. By optimizing patient outcomes while minimizing off-target effects, this innovative approach could drastically improve the management of leptomeningeal metastases. This treatment not only represents a significant leap in neuro-oncology but also reflects the collaborative efforts of local research institutions and the therapeutic advancements facilitated by community involvement.
Future Implications of the Research
The upcoming presentation aims to shed light on the safety, efficacy, and broader potential of REYOBIQ™ in treating this dire condition. With neuro-oncology being a rapidly evolving field, the need for innovative solutions is paramount. Plus Therapeutics leads the charge in reckoning with significant unmet medical needs, advocating for both individual patient care and systemic advancements within the healthcare landscape.
Community Engagement and Support
The SABCS showcases not only the latest scientific advancements but also the strength of our community in supporting healthcare innovation. As local residents come together to participate and learn from pioneering research, it fosters a collaborative environment where ideas and initiatives thrive. Engaging in events like the SABCS is vital, as it amplifies the local dialogue surrounding cancer treatment innovations and offers support to those affected by this disease.
Conclusion
The acceptance of Plus Therapeutics’ abstract to present at the 2025 SABCS serves as a testament to San Antonio’s growing reputation as a hub for cancer research and treatment innovation. With a focus on new approaches for leptomeningeal metastases, this event provides an opportunity for attendees to engage with some of the most promising developments in the field. The community’s support and involvement are crucial for continuing to foster advancements like those seen in this presentation. We encourage readers to stay informed and support local initiatives that promote health and wellness within our neighborhoods.
Frequently Asked Questions (FAQ)
What is the focus of Plus Therapeutics’ upcoming presentation at the 2025 San Antonio Breast Cancer Symposium?
The presentation will focus on the Phase 1 dose escalation study results of Rhenium (186Re) Obisbemeda (REYOBIQ™) for the treatment of leptomeningeal metastases (LM).
Who is presenting the study results at the symposium?
The study results will be presented by Dr. Andrew Brenner, M.D., Ph.D., Professor and Kolitz/Zachry Endowed Chair in Neuro-Oncology Research at the University of Texas Health Science Center at San Antonio.
When and where is the presentation scheduled?
The presentation is scheduled for Friday, December 12, 2025, from 7:39 am to 7:42 am CST at the Hemisfair 3 venue in the Henry B. Gonzalez Convention Center during the 2025 San Antonio Breast Cancer Symposium.
What are leptomeningeal metastases, and why are they significant?
Leptomeningeal metastases are a rare but severe complication of advanced cancers, affecting approximately 5% of patients with metastatic cancer.
What is REYOBIQ™, and how does it relate to the treatment of leptomeningeal metastases?
REYOBIQ™ is a novel injectable radiotherapy specifically formulated to deliver targeted high-dose radiation directly to central nervous system tumors, aiming to optimize patient outcomes while minimizing off-target risks.
What is the significance of Plus Therapeutics’ research in the field of neuro-oncology?
Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for challenging cancers of the central nervous system, with programs focused on leptomeningeal metastases and recurrent glioblastoma, utilizing advanced platform technologies to enhance clinical outcomes.
What are the expected outcomes of the upcoming presentation at the 2025 SABCS?
The presentation aims to provide further insights into the safety, efficacy, and potential of REYOBIQ™ in treating leptomeningeal metastases, contributing to the ongoing efforts to address significant unmet needs in neuro-oncology.
Key Features of the ReSPECT-LM Phase 1 Dose Escalation Study
| Feature | Description |
|---|---|
| Study Title | Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM): Phase 1 Dose Escalation Study Results |
| Presenter | Dr. Andrew Brenner, M.D., Ph.D., Professor and Kolitz/Zachry Endowed Chair in Neuro-Oncology Research at the University of Texas Health Science Center at San Antonio |
| Presentation Date and Time | Friday, December 12, 2025, from 7:39 am to 7:42 am CST |
| Location | Hemisfair 3, Henry B. Gonzalez Convention Center, San Antonio, Texas |
| Study Focus | Phase 1 dose escalation study results of REYOBIQ™ for the treatment of leptomeningeal metastases |
| Significance | Providing insights into the safety, efficacy, and potential of REYOBIQ™ in treating leptomeningeal metastases, addressing significant unmet needs in neuro-oncology |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN ANTONIO WRITER
The SAN ANTONIO STAFF WRITER represents the experienced team at HERESanAntonio.com, your go-to source for actionable local news and information in San Antonio, Bexar County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Fiesta San Antonio, San Antonio Stock Show & Rodeo, and Dia de los Muertos. Our coverage extends to key organizations like the Greater San Antonio Chamber of Commerce and United Way of San Antonio and Bexar County, plus leading businesses in retail, insurance, and energy that power the local economy such as H-E-B, USAA, and Valero Energy. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HEREHouston.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
